Becton Dickinson
Prezzo: 146.24Società e modello di business
Becton Dickinson (BDX) is a global medical technology company that develops, manufactures, and sells a broad range of medical devices, instrument systems, and reagents. Its core products include syringes, needles, and blood collection systems, primarily serving healthcare institutions. Major business segments encompass BD Medical, BD Life Sciences, and BD Biosciences, with revenue sources derived from product sales and services in these segments.
Profilo di investimento
The investment profile of Becton Dickinson is more aligned with dividends, given its consistent dividend yield. The stock may appeal to investors seeking income rather than aggressive growth, reflecting a balanced approach. However, recent performance indicators suggest caution, indicating potential risks for investors.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- 3.95 OK
- Ricavi QoQ — crescita dei ricavi trimestre su trimestre
- -10.2% ↓
- Sorpresa EPS
- 31.7% meglio del previsto
- Volatilità 20g
- 1.3% stabile
- Rendimento dividendo
- 2.6% moderato ultima data ex-dividendo: 2026-03-10
Traccia in portafoglio
Grafico prezzo
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-06-09 03:33 | Mantieni | Vendi | Weak fundamentals and negative momentum raise concerns. |
| 2026-06-01 02:32 | Vendi | Mantieni | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-08 15:08 | — | Vendi | Weak fundamentals and negative momentum raise concerns. |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-05-11 09:26 | Barclays | Target alzato | 202 → 204 | 149.43 |
| 2026-04-17 11:40 | Piper Sandler | Target abbassato | 170 → 159 | 154.82 |
| 2026-04-14 11:17 | RBC Capital | Target abbassato | 195 → 175 | 155.43 |
Ancora nulla